BridgeBio Oncology Therapeutics, Inc.
$9.26
▼
-1.33%
2026-04-21 05:34:01
bbotx.com
NGM: BBOT
Explore BridgeBio Oncology Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$748.31 M
Current Price
$9.26
52W High / Low
$14.87 / $8.08
Stock P/E
158.62
Book Value
$5.14
Dividend Yield
—
ROCE
-35.28%
ROE
-48.23%
Face Value
—
EPS
$-4.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
92
Beta
0.51
Debt / Equity
0.67
Current Ratio
12.34
Quick Ratio
12.34
Forward P/E
-4.1
Price / Sales
—
Enterprise Value
$249.58 M
EV / EBITDA
-1.72
EV / Revenue
—
Rating
None
Target Price
$25.38
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 2. | Candel Therapeutics, Inc. | $7.22 | — | $466.58 M | — | -41.46% | -64.58% | $7.25 / $4.34 | $0.95 |
| 3. | Serina Therapeutics, Inc. | $2.1 | — | $25.86 M | — | -709.03% | -81.59% | $7.92 / $1.22 | $-0.46 |
| 4. | NewAmsterdam Pharma Company N.V. | $33.82 | — | $3.89 B | — | -33.02% | -28.29% | $42 / $15.82 | $5.97 |
| 5. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
| 6. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 7. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -43.41 M | -49.18 M | -30.09 M | -23.14 M | -21.88 M | — |
| Net Profit | -38.8 M | -44.76 M | -28.43 M | -22.05 M | -19.69 M | — |
| EPS in Rs | -0.48 | -0.56 | -0.36 | -0.28 | -0.25 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0 M | 0 M | 0 M |
| Operating Profit | -145.82 M | -80.86 M | -64.77 M |
| Net Profit | -134.04 M | -74.28 M | -64.7 M |
| EPS in Rs | -1.67 | -0.93 | -0.81 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 448.38 M | 164.3 M | 5.94 M |
| Total Liabilities | 37.28 M | 342.94 M | 121.58 M |
| Equity | 411.1 M | -178.64 M | -115.64 M |
| Current Assets | 432.4 M | 158.69 M | 3.94 M |
| Current Liabilities | 35.04 M | 19.58 M | 16.77 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -113.89 M | -55.03 M | -52.08 M |
| Investing CF | 73.33 M | -120.53 M | -2.82 M |
| Financing CF | 383.4 M | 206.29 M | 55.12 M |
| Free CF | -114.5 M | -55.08 M | -52.49 M |
| Capex | -0.61 M | -0.05 M | -0.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -80.47% | -14.8% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.